Dry powder formulations for inhalation require a smaller aerodynamic diameter for usage at high altitude.

[1]  Peng Han,et al.  Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury , 2023, Molecules.

[2]  M. S. Islam,et al.  Nanoparticle transport and deposition in a heterogeneous human lung airway tree: An efficient one path model for CFD simulations. , 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  E. Selg,et al.  Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. , 2022, International journal of pharmaceutics.

[4]  A. Aliverti,et al.  Functional analysis of the airways after pulmonary lobectomy through computational fluid dynamics , 2022, Scientific Reports.

[5]  F. Mohamadi,et al.  A Review on Applications of CFD Modeling in COVID-19 Pandemic , 2022, Archives of Computational Methods in Engineering.

[6]  S. Ibrić,et al.  Comparative Assessment of In Vitro and In Silico Methods for Aerodynamic Characterization of Powders for Inhalation , 2021, Pharmaceutics.

[7]  A. Aliverti,et al.  Computational Fluid Dynamics (CFD) Analysis of Subject-specific Bronchial Tree Models in Lung Cancer Patients , 2021, 2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC).

[8]  E. Molina-Grima,et al.  CFD-based prediction of initial microalgal adhesion to solid surfaces using force balances , 2021, Biofouling.

[9]  H. Chan,et al.  Dry Powder Pharmaceutical Biologics for Inhalation Therapy. , 2021, Advanced drug delivery reviews.

[10]  H. Ghofrani,et al.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders , 2021, International journal of environmental research and public health.

[11]  Raghvendra Gupta,et al.  Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications , 2021, Pharmaceutics.

[12]  D. Tripathi,et al.  Bioengineered bioreactors: a review on enhancing biomethane and biohydrogen production by CFD modeling , 2021, Bioengineered.

[13]  Runyu Yang,et al.  Role of CFD based in silico modelling in establishing an in vitro-in vivo correlation of aerosol deposition in the respiratory tract. , 2020, Advanced drug delivery reviews.

[14]  C. Darquenne.  Deposition Mechanisms. , 2020, Journal of Aerosol Medicine.

[15]  M. Nikinmaa.  Finally, a promising model for high‐altitude pulmonary edema (HAPE)—A Mountaineers’ Malady , 2020, Acta physiologica.

[16]  Y. Kagawa,et al.  Small-Scale Spherical Granulation Using a Planetary Centrifugal Mixer. , 2020, Chemical and pharmaceutical bulletin.

[17]  Basanth Babu Eedara,et al.  Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. , 2019, International journal of pharmaceutics.

[18]  C. Burger,et al.  Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy , 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.

[19]  M. Sommerfeld,et al.  Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  M. Hindle,et al.  Use of computational fluid dynamics deposition modeling in respiratory drug delivery , 2018, Expert opinion on drug delivery.

[21]  Xiaoting Yang,et al.  Sinomenine protects against E.coli-induced acute lung injury in mice through Nrf2-NF-κB pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  P. Young,et al.  Dosing challenges in respiratory therapies , 2018, International journal of pharmaceutics.

[23]  S. Ibrić,et al.  Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically‐based pharmacokinetic (PBPK) modelling , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Michael Y. T. Chow,et al.  Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. , 2017, International journal of pharmaceutics.

[25]  C. Grandmont,et al.  Aerosol transport throughout inspiration and expiration in the pulmonary airways , 2017, International journal for numerical methods in biomedical engineering.

[26]  I. Arévalo-Rodriguez,et al.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. , 2017, The Cochrane database of systematic reviews.

[27]  Kazunori Kadota,et al.  Assistance for Predicting Deposition of Tranilast Dry Powder in Pulmonary Airways by Computational Fluid Dynamics , 2017, Journal of Pharmaceutical Innovation.

[28]  Boyi Niu,et al.  Influence of physical properties of carrier on the performance of dry powder inhalers , 2016, Acta pharmaceutica Sinica. B.

[29]  M. Delichatsios,et al.  Blow-out limits of nonpremixed turbulent jet flames in a cross flow at atmospheric and sub-atmospheric pressures , 2015 .

[30]  S. Lee,et al.  Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data , 2015, Pharmaceutical Research.

[31]  A. Nitsch-Osuch,et al.  High altitude pulmonary edema in mountain climbers , 2015, Respiratory Physiology & Neurobiology.

[32]  Mao-tsun Lin,et al.  High-altitude pulmonary edema can be prevented by heat shock protein 70–mediated hyperbaric oxygen preconditioning , 2014, The journal of trauma and acute care surgery.

[33]  L. Chua,et al.  Perspective on CFD studies of coronary artery disease lesions and hemodynamics: A review , 2014, International journal for numerical methods in biomedical engineering.

[34]  E. Swenson,et al.  Clinical practice: Acute high-altitude illnesses. , 2013, The New England journal of medicine.

[35]  Waseem Kaialy,et al.  Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. , 2012, International journal of pharmaceutics.

[36]  R. Löbenberg,et al.  Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. , 2011, Therapeutic delivery.

[37]  Raymond Lau,et al.  Effect of particle formulation on dry powder inhalation efficiency. , 2010, Current pharmaceutical design.

[38]  P. Hackett,et al.  Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness , 2010, Wilderness & environmental medicine.

[39]  Beom-Jin Lee,et al.  Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats , 2005, Biopharmaceutics & drug disposition.

[40]  J. Borer,et al.  Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon. , 1987, Chest.

[41]  J. Sommer,et al.  Pharmacokinetics and metabolism of nifedipine. , 1983, Hypertension.

[42]  S. Watano,et al.  Effect of Particle-Wall Interaction and Particle Shape on Particle Deposition Behavior in Human Respiratory System. , 2019, Chemical & pharmaceutical bulletin.

[43]  S. Wagner,et al.  Computational Fluid Dynamics (CFD) , 2000 .

[44]  Computer Methods and Programs in Biomedicine CFD simulation of porous microsphere particles in the airways of pulmonary fibrosis , 2022 .